Inactive Instrument

Admedus Ltd Share Price Australian S.E.

Equities

Medical Equipment, Supplies & Distribution

End-of-day quote Australian S.E.
- - Intraday chart for Admedus Ltd

Financials

Sales 2024 * 60L 39.75L 0 33Cr Sales 2025 * 60L 39.75L 0 33Cr Capitalization 37Cr 25Cr 0 2.06TCr
Net income 2024 * -7.9Cr -5.23Cr - -435.86Cr Net income 2025 * -8.5Cr -5.63Cr - -468.96Cr EV / Sales 2024 * 58 x
Net cash position 2024 * 2.5Cr 1.66Cr 0 137.93Cr Net cash position 2025 * 2.5Cr 1.66Cr 0 137.93Cr EV / Sales 2025 * 58 x
P/E ratio 2024 *
-5.17 x
P/E ratio 2025 *
-5.49 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 83.81%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 56 10/14/10
Director of Finance/CFO - 23/18/23
Chief Tech/Sci/R&D Officer - 06/21/06
Members of the board TitleAgeSince
Chairman 72 10/14/10
Director/Board Member - 31/18/31
Chief Executive Officer 56 10/14/10
More insiders
Anteris Technologies Ltd is an Australia-based structural heart company. The Company is engaged in designing, developing, and commercializing medical devices. The Company’s lead product, DurAVR, is a transcatheter heart valve (THV) for treating aortic stenosis. DurAVR THV is made using ADAPT tissue, its patented anti-calcification tissue technology. DurAVR THV is a novel first-in-class biomimetic valve made from a single piece of native-shaped tissue. It is designed to mimic the performance of a pre-disease human aortic valve. Its balloon expandable ComASUR Delivery System provides controlled deployment and accurate placement of the DurAVR THV valve, designed to achieve precise alignment with the heart’s native commissures to achieve ideal valve positioning.
Calendar
More about the company